- Previous Close
1,409.00 - Open
1,409.00 - Bid --
- Ask --
- Day's Range
1,402.70 - 1,428.00 - 52 Week Range
729.10 - 1,639.00 - Volume
272,783 - Avg. Volume
905,887 - Market Cap (intraday)
254.775B - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
15.55 - EPS (TTM)
91.44 - Earnings Date Nov 12, 2024
- Forward Dividend & Yield 12.50 (0.89%)
- Ex-Dividend Date Aug 23, 2024
- 1y Target Est
1,048.43
NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
www.natcopharma.co.in4,016
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: NATCOPHARM.NS
View MorePerformance Overview: NATCOPHARM.NS
Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NATCOPHARM.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NATCOPHARM.NS
View MoreValuation Measures
Market Cap
252.46B
Enterprise Value
238.54B
Trailing P/E
15.42
Forward P/E
16.86
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.01
Price/Book (mrq)
4.31
Enterprise Value/Revenue
6.00
Enterprise Value/EBITDA
12.74
Financial Highlights
Profitability and Income Statement
Profit Margin
37.63%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
43.49B
Net Income Avi to Common (ttm)
16.36B
Diluted EPS (ttm)
91.44
Balance Sheet and Cash Flow
Total Cash (mrq)
18.49B
Total Debt/Equity (mrq)
6.34%
Levered Free Cash Flow (ttm)
--